Reviewed by Michael Gill, B. Sc.
10 Iga Nephropathy Clinical Trials Near Me
Top Hospitals for Iga Nephropathy Clinical Trials
Image of Amicis Research Center in California.
Amicis Research Center
3Active Trials
0All Time Trials for Iga Nephropathy
2019First Iga Nephropathy Trial
Image of Academic Medical Research Institute in California.
Academic Medical Research Institute
Los Angeles
2Active Trials
0All Time Trials for Iga Nephropathy
2020First Iga Nephropathy Trial
Top Cities for Iga Nephropathy Clinical Trials
Iga Nephropathy Clinical Trials by Phase of Trial
Phase 1 & 2 Iga Nephropathy Clinical Trials
1Active Iga Nephropathy Clinical Trials
1Number of Unique Treatments
11Number of Active Locations
Iga Nephropathy Clinical Trials by Age Group
Most Recent Iga Nephropathy Clinical Trials
Top Treatments for Iga Nephropathy Clinical Trials
Treatment Name
Active Iga Nephropathy Clinical Trials
All Time Trials for Iga Nephropathy
First Recorded Iga Nephropathy Trial
Telitacicept 240mg

What Are IgA Nephropathy Clinical Trials?

IgA nephropathy, also known as Berger's disease, is characterized by predominant IgA deposition in the glomerular mesangium. Simply put, it is a kidney disease in which IgA deposits build up in the kidney and cause inflammation that damages the kidney tissues. It affects the kidneys by attacking the glomeruli, which are sets of looping blood vessels in the nephrons. The buildup of IgA deposits inflames the glomeruli, causing the kidneys to leak blood and protein into the urine.

Many ongoing IgA nephropathy clinical trials study the efficiency of different drugs and treatments for positive outcomes.

Why Is IgA Nephropathy Being Studied Through Clinical Trials?

IgA nephropathy is one of the most common kidney diseases and can occur at any age. The incidence rate has been estimated at 2–10 per 100,000 person-years. In the U.S, IgA nephropathy is twice as likely to appear in men than in women, and while found in people all over the world, it is more common among Asians and Caucasians.

Moreover, the disease course ranges from asymptomatic nonprogressive to aggressive, with up to one in four patients suffering from ESRD within 20 years from diagnosis, requiring RRT. IgA nephropathy is a chronic kidney disease and can lead to end-stage renal disease.

What Are The Types of Treatments Available For IgA Nephropathy?

Treatments regarding IgA nephropathy are mostly centered around pharmacotherapy. A clinical trial is underway to study the efficiency and safety of LNP023 in primary IgA Nephropathy patients. The study will be pivotal for the registration of LNP023 in IgA Nephropathy patients who demonstrate a clinically meaningful reduction in proteinuria by LNP023 vs. placebo as assessed by reduction in urine protein to creatinine ratio (UPCR) sampled from a 24-hour urine collection at an IA at nine months.

Current treatment for IgA nephropathy includes antiplatelet and anticoagulant drugs.

What Are Some Recent Breakthrough Clinical Trials For IgA Nephropathy?

Following are some of the recent studies conducted on IgA nephropathy:

2011: Current Therapy for IgA Nephropathy - A small randomized trial suggested the benefit of dipyridamole (75 mg three times daily and warfarin [INR 1.3 to 1.5]) as compared with no treatment.

2019: Biomarkers for IgA Nephropathy - this study focuses on early diagnosis of the disease for curative treatment strategies and approaches. While the renal biopsy is commonly used, this study found that disease-oriented specific serum and urine biomarkers may help screen potential IgAN with isolated hematuria, earlier diagnosis, disease activity, and eventually, response to treatment.

Who Are Some Of The Key Opinion Leaders / Researchers / Institutions Conducting IgA Nephropathy Clinical Trial Research?

American Society Of Nephrology

The American Society Of Nephrology is the largest professional society that fights against kidney diseases by educating health professionals, sharing new knowledge, and advancing research.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIDDK conducts clinical trials to identify new ways to prevent, detect, or treat kidney diseases. It supports basic and clinical research on kidney development and disease, including causes, progression, identification, and testing of possible treatments.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 21st, 2021

Last Reviewed: November 21st, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Reich HN, Floege J. How I Treat IgA Nephropathy. Clin J Am Soc Nephrol. 2022 Aug;17(8):1243-1246. doi: 10.2215/CJN.02710322. Epub 2022 Jun 8.